Table 2.
CSR activities by pharmaceutical firm
| A | B | C | D | E | F | |
|---|---|---|---|---|---|---|
| Product Involvement | ||||||
| Donation | X | X | X | X | X | |
| Differential pricing sales for resource poor countries | X | X | X | X | X | X |
| Special licensing agreements for resource-poor countries | X | X | X | X | ||
| Health Systems Strengthening | ||||||
| Training of health care workers | X | X | X | X | ||
| Improved local manufacturing | X | X | X | |||
| Increased product distribution capacity | X | X | X | X | X | X |
| Infrastructure investment | X | X | X | |||
| Supply-chain support | X | X | X | X | ||
| Private or informal provider engagement | X | X | X | X | X | |
| Promoting uptake of health insurance | X | X | ||||
| Miscellanous | ||||||
| Loan & Microfinance programs | X | X | X | |||
| mHealth initiatives | X | X | X | X | X | |
| Social marketing | X | |||||
| Health issue awareness campaigns | X | X | X | X | ||
| Advocacy and policy | X | |||||
| Targeted Research & Development* | X | X | X | X | X | X |
| International employee placement program | X | X | X | X | ||
*Specifically to meet developing country health needs or products with no commercial potential.